Fortress Biotech, Inc.: diluted earnings per share

What this measure means

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Basic earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Fortress Biotech's 2024 and 2025 common-share EPS uses dollar thousands and full shares. The 2025 consolidated loss becomes $6.815 million of income attributable to Fortress after noncontrolling interests; $8.697 million of preferred and subsidiary deemed dividends then produces a $1.882 million common-stockholder loss. The 2024 common loss similarly includes the dividend adjustment. EPS is not calculated from consolidated loss or Fortress-attributable income alone. The filing excludes potential shares when anti-dilutive during net-loss periods. Read the source filing.

Selected filing history

Related financial histories

• Fortress Biotech, Inc.: total assets
• Fortress Biotech, Inc.: total liabilities
• Fortress Biotech, Inc.: stockholders equity
• Fortress Biotech, Inc.: cash and cash equivalents
• Fortress Biotech, Inc.: net income or loss
• Fortress Biotech, Inc.: operating cash flow
• Fortress Biotech, Inc.: capital expenditure payments
• Fortress Biotech, Inc.: revenue
• Fortress Biotech, Inc.: financing cash flow
• Fortress Biotech, Inc.: investing cash flow
• Fortress Biotech, Inc.: retained earnings or deficit
• Fortress Biotech, Inc.: basic weighted-average shares
• Fortress Biotech, Inc.: diluted weighted-average shares
• Fortress Biotech, Inc.: basic earnings per share
• Fortress Biotech, Inc.: income tax expense or benefit
• Fortress Biotech, Inc.: net property, plant and equipment
• Fortress Biotech, Inc.: share-based compensation expense
• Fortress Biotech, Inc.: operating income or loss
• Fortress Biotech, Inc.: current assets
• Fortress Biotech, Inc.: interest expense
• Fortress Biotech, Inc.: current liabilities
• Fortress Biotech, Inc.: current accounts payable
• Fortress Biotech, Inc.: goodwill carrying amount
• Fortress Biotech, Inc.: net finite-lived intangible assets
• Fortress Biotech, Inc.: net current accounts receivable
• Fortress Biotech, Inc.: operating expenses
• Fortress Biotech, Inc.: net inventory
• Fortress Biotech, Inc.: selling, general and administrative expense
• Fortress Biotech, Inc.: research and development expense

Inspect the source

Entity

Fortress Biotech, Inc. / CIK 0001429260

Captured

2026-09-20T09:02:19.576Z

SEC response SHA-256

78daf3b5c8c8b3d82976f96053549696f5b6bfa1fb1158d29e0dd97a741a012d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001429260.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))